February 3, 2026
Why do health apps fail? Sanofi's Chema critiques pharma's "shiny toy syndrome" & urges building digital solutions on human behavior.
January 27, 2026
AI in healthcare is no longer hype; it's infrastructure. This episode provides a 6-step framework to separate signal from noise.
MFN policy threatens to upend pharma's global launch strategy, forcing a difficult choice between US price protection and international access.
Two-thirds of pharma launches fail. Global strategist Marek Rommel reveals why execution, soft skills, and consistency trump big budgets.
Ethical persuasion isn't manipulation; it's a moral craft rooted in purpose. Jill Donohue on turning tragedy into a mission to rebuild trust.
Top oncologist reveals why most cancer drugs fail and how learning from these setbacks is the key to breakthroughs in immuno-oncology and beyond.
Scientists are building living computers with human neurons to create energy-efficient AI. Dr. Evelina Cortes of Final Spark explains how.
Dr. Aubrey de Grey reframes aging as a solvable engineering problem, not destiny, outlining a path to 'longevity escape velocity' via damage repair.
Heart disease is a silent killer, even for the healthy. Professor Mache Banach explains why understanding and managing your LDL cholesterol is key.
Redefine impact in Medical Affairs: It's not what you do, but what changes. Dr. Karl Ossie on leadership, purpose, and system-level change.
January 25, 2026
AI is rapidly automating pharma roles. This isn't job loss, it's job redesign. Learn the 12-month roadmap to evolve and lead the change.
The fight against cancer isn't about one cure, but many breakthroughs. GSK's Dr. Solanki on oncology's evolution, tech, and collaboration.
CellSci CEO Gerd Kirsten discusses Multikind, a pre-surgery immunotherapy, and the decades-long battle against scientific and financial hurdles.
Expert Uday Bos on moving from transactional pharma sales to empathetic CX, fostering true gender equality, and leading with authenticity.
Redefining pharma leadership: moving beyond hierarchy to embrace shared leadership, authentic customer experience, and purpose-driven diversity.
Pharma leader Dr. Aru Pramanik redefines market access: it's a collaborative ecosystem, not just pricing, to get life-changing drugs to patients.
Stop optimizing every part of your system. Dr. Alan Bernard explains how to find and fix the single bottleneck holding you back using the Theory of Constraints.
Veeva's Florian Schnappauf on how a unified CRM, purpose-built for life sciences and powered by AI, is key to solving pharma's 2030 launch challenge.
Biotech CEO Thayne Wetting on leading Fibrogen's transformation. Insights on resilience, patient-first innovation, and navigating market volatility.
Drug Diaries' 1st anniversary celebrates the power of authentic conversation over perfection, building a global community around real human stories.
Delphi Diagnostics CEO Susan Tucci discusses a revolutionary blood test using AI to detect cancer early, making life-saving tech accessible to all.
Genpact's Aditya Gherola discusses how AI is revolutionizing life sciences, from drug discovery and regulatory affairs to patient experience.
A new drug, Zelenorstat, fights cancer and viruses by disabling their cellular 'GPS,' offering a revolutionary, precise treatment approach.
Carolina Kazara-Korea on mastering pharma omnichannel: Unify data, leverage AI for real-time personalization, and keep engagement human-centric.
Veeva's Emma Hyland on transforming pharma content with AI, strategy, and compliance. It's not about more content, but smarter content.
Experts discuss bridging the childhood cancer survival gap through collaboration, holistic care, and empowering local healthcare systems.
A senior physiotherapist shares her harrowing journey with endometriosis, battling debilitating pain and a dismissive medical system.
Dr. Steve Axelord of G-Tech Medical discusses a wearable patch that decodes gut health, shifting GI diagnosis from subjective symptoms to objective data.
A father's mission to change perceptions of Type 1 Diabetes, focusing on the emotional burden through a powerful new film series.
January 24, 2026
Engers Fernandez discusses healthcare tech's future, tackling innovation hurdles like legacy EMRs & envisioning AI-driven patient education.
Professor Olshansky argues for prioritizing healthspan over lifespan, exploring the economic 'longevity dividend' and biological limits to aging.
Raghav Sehgal discusses using AI to decode aging, from organ-specific clocks to data bias and the future of personalized longevity tech.
January 23, 2026
A cancer survivor's journey from diagnosis to advocacy, calling for true patient empowerment, better information, and a more humane system.
Zohas CEO Tim Wright on navigating digital health: strategies for funding, market fit, partnerships, and overcoming startup hurdles.
Resolution Therapeutics CEO Amir Hefni on macrophage cell therapy to reverse liver disease, backed by a recent $63.5M Series B financing.
Teva's digital head Alyssa Finoglio on leading pharma's tech revolution, from GenAI's impact to balancing short & long-term digital strategy.
January 22, 2026
Discover lifespan housing with Scott Fulton. Design homes for lifelong wellness, focusing on community, tech, and forward-looking life planning.
January 14, 2026
GSK's Daniel Lowther explains how biomarkers and immuno-oncology are revolutionizing cancer care by personalizing treatments and leveraging our immune system.
January 13, 2026
Pharma leader Rakesh Vashishta discusses the 30-year evolution of customer engagement, from paper aids to predictive AI and omnichannel strategies.
Pharma procurement leader Helen Thompson shares insights on building strategic vendor partnerships, ethical sourcing, and essential career skills.
Dr. Bede Ports discusses how condensate science is revolutionizing drug discovery, targeting 'undruggable' proteins like MYC in cancer and ALS.
January 12, 2026
MIT researcher Somesh Mahapatra discusses leveraging AI and chemistry to revolutionize gene therapy for Duchenne Muscular Dystrophy (DMD).
Natural Killer cells show promise in combating age-related diseases by selectively clearing senescent cells, a key driver of aging.
January 4, 2026
Why do 2/3 of pharma launches fail? Global strategist Marek reveals it's not the science, but a crisis of execution and soft skills.
